Compare GOAI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOAI | BMEA |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | 37 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.9M | 95.7M |
| IPO Year | 2023 | 2021 |
| Metric | GOAI | BMEA |
|---|---|---|
| Price | $1.66 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.83 |
| AVG Volume (30 Days) | 195.5K | ★ 446.5K |
| Earning Date | 04-10-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 966.67 | 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,037,328.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.59 | N/A |
| 52 Week Low | $1.42 | $0.87 |
| 52 Week High | $6.67 | $2.99 |
| Indicator | GOAI | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 30.63 | 56.49 |
| Support Level | N/A | $1.21 |
| Resistance Level | $2.68 | $1.44 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 37.10 | 96.77 |
Eva Live Inc is a United States-based technology company that has developed an automated and intelligent advertiser campaign management platform, Eva Platform, which enables advertisers ('customers, clients') to buy advertising space on several digital channels to reach their desired audience. The company also works with Businesses that utilize its in-house digital marketing capabilities, including advice, creative services, account management, production of advertising materials, media planning, and buying.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.